Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 381 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastatic HER2-negative Breast Clear all
Recruiting Phase 2 Interventional

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194
View directory record Official record
Conditions
B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
Interventions
18F-FSPG, 18F-FDG
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

NCT04573231
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 2 Interventional Results available

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

NCT03070002
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer
Interventions
Denosumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 2 Interventional

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions
Alpelisib, Fulvestrant, Aromatase inhibitor
Drug
Lead sponsor
Marina N Sharifi
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT02311933
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
559
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

NCT04059484
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432
View directory record Official record
Conditions
Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions
NUV-1511
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Tamoxifen, Prophylactic Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

NCT05261269
View directory record Official record
Conditions
HER2-negative Metastatic Breast Cancer
Interventions
DAN-222, Niraparib
Drug
Lead sponsor
Dantari, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
La Jolla, California • Santa Monica, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258451
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

NCT02411656
View directory record Official record
Conditions
Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

NCT01948843
View directory record Official record
Conditions
HER2 Negative Metastatic Breast Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT01862081
View directory record Official record
Conditions
Breast Cancer, Non-small Lung Cancer
Interventions
Docetaxel, GDC-0032, Paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 1 Interventional

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 2 Interventional Results available

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

NCT02389764
View directory record Official record
Conditions
Breast Cancer
Interventions
BIBF 1120, Phone Call
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 14, 2026, 10:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706
View directory record Official record
Conditions
Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Interventions
Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
Drug · Combination Product
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
17
States / cities
Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 14, 2026, 10:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Commack, New York • Harrison, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

NCT01846091
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

NCT02536794
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study, Tremelimumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 14, 2026, 10:33 AM EDT